Scarica l'app Stockscreener
5.7116
0.38%
0.0216
Dopo l'orario di chiusura:
5.55
-0.1616
-2.83%
Precedente Chiudi:
$5.69
Aprire:
$5.58
Volume 24 ore:
37,368
Relative Volume:
0.25
Capitalizzazione di mercato:
$3.54M
Reddito:
$644.60K
Utile/perdita netta:
$-9.87M
Rapporto P/E:
-0.00682
EPS:
-837.9618
Flusso di cassa netto:
$-9.02M
1 W Prestazione:
+4.42%
1M Prestazione:
-18.17%
6M Prestazione:
-79.60%
1 anno Prestazione:
-94.81%
Intervallo 1D:
$5.3221
$5.9567
Intervallo di 1 settimana:
$5.2877
$5.9567
Portata 52W:
$5.2877
$112.85
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Nome
Biodexa Pharmaceuticals Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BDRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
5.7116 | 3.32M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-08 | Iniziato | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Borsa (BDRX) Ultime notizie
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Biodexa announces enrollment of first two patients in Phase 3 Serenta trial - MSN
Biodexa Pharmaceuticals (NASDAQ:BDRX) Trading 2.3% Higher – Time to Buy? - Defense World
Biodexa Announces Enrolment of First Patients into Pivotal - GlobeNewswire
[6-K] Biodexa Pharmaceuticals plc American Depositary Shs Current Report (Foreign Issuer) - Stock Titan
$7.3 Billion Market Opportunity: Biodexa's eRapa Could Become First-Ever Drug Treatment for FAP Cancer Risk - Stock Titan
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Biodexa Pharmaceuticals (NASDAQ:BDRX) Cut to Strong Sell at Wall Street Zen - Defense World
Biodexa completes ADR ratio change to 1:100,000 ordinary shares By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals Implements ADR Ratio Change - TipRanks
ADR Ratio Change Effective | BDRX Stock News - GuruFocus
Biodexa completes ADR ratio change to 1:100,000 ordinary shares - Investing.com
Biodexa Pharmaceuticals PLC ADR ratio changes to 1:100,000. - AInvest
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - AInvest
ADR Ratio Change Effective - GlobeNewswire
Biodexa Implements Major ADR Restructuring: 10,000 to 100,000 Shares Per ADR Change Now Active - Stock Titan
Biodexa advances FAP treatment with phase 3 trial initiation By Investing.com - Investing.com Nigeria
Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market - Stock Titan
Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest
MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest
ADR Ratio Change - GlobeNewswire
Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan
Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India
Biodexa files European clinical trial application for FAP treatment - Investing.com
Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan
SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewswire
Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com
Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan
Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment - Stock Titan
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) - GlobeNewswire
Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com
Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions - Stock Titan
Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals changes share nominal value - Investing.com
Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India
Biodexa shareholders approve all resolutions at general meeting - Investing.com
Biodexa Secures Full Shareholder Approval for Share Value Reset and Enhanced Director Authority - Stock Titan
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes - GlobeNewswire
Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan
Biodexa secures additional $3M for cancer drug trial - Investing.com
Biodexa Announces Award of Additional $3.0M Grant from - GlobeNewswire
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com
Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India
Biodexa Pharmaceuticals Plc Adr Azioni (BDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):